Acorda Therapeutics Inc (ACOR) was Resumed by Leerink Partners to “Mkt Perform” and the brokerage firm has set the Price Target at $25. Leerink Partners advised their investors in a research report released on Oct 4, 2016.
On the company’s financial health, Acorda Therapeutics Inc reported $0.07 EPS for the quarter, missing the analyst consensus estimate by $ -0.17 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $127.45 million for the quarter, compared to analysts expectations of $129.82 million. The company’s revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.31 EPS.
Acorda Therapeutics Inc opened for trading at $20.75 and hit $21.15 on the upside on Friday, eventually ending the session at $20.88, with a gain of 1.16% or 0.24 points. The heightened volatility saw the trading volume jump to 9,24,257 shares. Company has a market cap of $963 M.
In a different news, on Sep 27, 2016, Jane Wasman (President, Intl and GC) sold 500 shares at $27.32 per share price. According to the SEC, on Jun 24, 2016, David Lawrence (Chief of Business Operations) sold 500 shares at $25.09 per share price. On Jun 10, 2016, Steven M Rauscher (director) sold 1,086 shares at $27.83 per share price, according to the Form-4 filing with the securities and exchange commission.
Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinsons disease epilepsy heart failure MS and spinal cord injury.